ABA Therapy and Autism Services M&A Multiples in 2026

Applied Behavior Analysis (ABA) and broader autism services have been one of the most active behavioral health M&A segments of the past decade. After a peak in 2020–2021 driven by aggressive PE platform building, the market has reset to a more selective and quality-focused environment in 2026 — but it remains highly active for the right agencies.

This guide covers how ABA agencies are valued today, what buyers look for, how multiples have evolved, and what owners considering a sale should understand about the current market.

---

ABA Market Context Heading Into 2026

The ABA M&A market has gone through three distinct phases in recent years:

2018–2021: Platform building and aggressive multiples. Multiple PE sponsors backed national and regional ABA platforms, and acquisition multiples were aggressive. Mid-market ABA agencies routinely traded at 8–10× EBITDA, with platform deals often higher. Easy capital, rapid growth assumptions, and intense competition for assets supported elevated pricing.

2022–2023: Reset. Higher interest rates, payer scrutiny on ABA utilization patterns, audit and compliance enforcement (particularly in some Medicaid markets), and slower-than-projected growth at some platforms produced a market reset. Multiples compressed, several platform-level deals were repriced or restructured, and the buyer pool became more selective.

2024–2026: Selective re-acceleration. The current market has stabilized at multiples meaningfully lower than the 2020–2021 peak but still attractive for quality operators. Buyers are more disciplined on clinical model, payer mix quality, BCBA staffing infrastructure, and compliance posture.

---

ABA Valuation Multiples in 2026

Agency Profile	EBITDA Range	Typical Multiple
Sub-scale single-state ABA	$300K–$750K	4.0× – 5.5×
Mid-market regional ABA	$750K–$2.5M	5.0× – 6.5×
Multi-state platform ABA	$2.5M–$7M	6.0× – 7.5×
Large platform ABA with strong clinical model	$7M+	7.0× – 9.0×+

Multiples vary materially by:

• Commercial vs Medicaid payer mix
• Geographic positioning
• Clinical model integrity (medically necessary care orientation)
• BCBA recruiting and retention performance
• Audit and compliance history
• Growth trajectory and pipeline

---

What Buyers Look For

BCBA Recruiting and Retention

Board Certified Behavior Analysts (BCBAs) are the credentialed clinical leaders of ABA programs and the chronic supply constraint of the industry. Buyers diligence:

• Number of BCBAs on staff and capacity utilization
• BCBA turnover rate — industry benchmark 25–40%; under 20% is exceptional
• Time-to-fill for BCBA positions
• BCBA-to-RBT ratio and supervision capacity
• Recruiting infrastructure — pipeline, sourcing channels, conversion
• Career path and engagement structure

ABA agencies with strong BCBA infrastructure command meaningful multiple premiums because the buyer is acquiring durable clinical capacity rather than just a current roster.

RBT Staffing and Training Model

Registered Behavior Technicians (RBTs) deliver the bulk of direct ABA hours. The training model, supervision structure, retention infrastructure, and capacity utilization of RBTs all factor into diligence.

Agencies with structured RBT training programs, low turnover, and high productive utilization are valued more highly than agencies with constant churn and inefficient staffing.

Payer Mix and Rate Quality

The payer mix matters significantly:

• Commercial-heavy — typically valued at higher multiples due to better rates, lower audit exposure, and stronger margin profile
• Medicaid-heavy — valuable but with more scrutiny on utilization, prior authorization compliance, and rate sustainability
• Tricare — present in some markets, with specific contract dynamics
• Self-pay and other — generally smaller share

Buyers also evaluate:

• Rate adequacy by payer and state
• Contract renewal cycles and terms
• Prior authorization friction and approval rates
• Retroactive payer audit history

Clinical Model Integrity

This is the diligence area that has changed most since 2022. Buyers now evaluate:

• Medically necessary care orientation — are services driven by clinical assessment and need, or by maximum-billable-hour assumptions?
• Treatment hour intensity vs clinical recommendation — agencies with utilization patterns inconsistent with clinical norms get scrutinized hard
• Outcome measurement — documentation of patient progress and clinical outcomes
• Discharge and step-down practices — agencies that retain patients beyond clinical justification face audit and ethical risk

Clinical model integrity has become a leading valuation variable. Agencies with strong, defensible clinical practices command premiums; agencies with utilization-driven models face deep discounts or buyer avoidance.

Authorized Hours Fill Rate

Similar to pediatric PDN, ABA agencies are evaluated on the percentage of authorized hours actually being delivered. Strong fill rates indicate effective scheduling, BCBA capacity, and RBT staffing. Weak fill rates indicate operational constraints — and may indicate upside opportunity for buyers with stronger infrastructure.

Compliance and Audit History

ABA Medicaid audits have been a meaningful regulatory enforcement area. Buyers diligence:

• State Medicaid audit history
• MCO audit findings
• Repayment and recoupment exposure
• Documentation quality and audit preparedness
• Compliance program structure

Agencies with clean audit histories and strong documentation practices command premiums. Agencies with material findings face structural discounts or escrow / earnout structures designed to manage risk.

Geographic Concentration

ABA is operationally intensive — supervision, RBT logistics, and clinical coordination benefit from density. Buyers value concentrated regional operations more than sprawl.

Growth Trajectory

Organic growth in census, authorized hours, and revenue is a key valuation driver. Buyers want defensible growth narratives — referral source expansion, geographic build-out, payer contract additions, capacity additions.

---

Common Diligence Issues in ABA M&A

1. BCBA / RBT misclassification — historical use of 1099 BCBAs or RBTs creates back-tax exposure and is typically required to be cleaned up
2. Authorization documentation gaps — incomplete or missing prior authorization documentation creates audit exposure
3. Treatment plan documentation issues — gaps in clinical documentation supporting treatment intensity
4. Concentration in a single MCO or state Medicaid program — single-payer concentration is a common diligence flag
5. Owner-operator clinical role dependence — if the founder is the de facto Clinical Director, replacement cost gets modeled as a discount
6. Recent audit findings or open repayment exposure — must be disclosed early; failing to disclose is deal-killing

---

Buyer Landscape in ABA

Active ABA buyers include:

• National PE-backed ABA platforms — Centerbridge / LEARN Behavioral, Centria Autism, Hopebridge, BlueSprig Pediatrics, and others
• Mid-market PE-backed regional ABA platforms — multiple regional builders with focused state or multi-state strategies
• Larger behavioral health strategics — Acadia Healthcare, Universal Health Services in select cases
• Platform sponsors looking for new ABA platforms — selective new platform investments by sponsors entering or re-entering the space

The buyer pool has narrowed since the 2020–2021 peak but remains deep enough that quality agencies attract competitive interest.

---

Strategic Implications for ABA Owners

If You Are Considering a Sale in the Next 12–24 Months

The 2026 market rewards operational and clinical quality. Priorities:

• Clean up BCBA / RBT classification (W-2 only)
• Document clinical model integrity (medically necessary care orientation)
• Address any open audit or repayment exposure
• Diversify payer mix where possible
• Strengthen BCBA recruiting and retention metrics
• Build defensible growth narrative

If You Have a Longer Horizon

The strategic playbook is broader:

• Build clinical leadership depth independent of the founder
• Invest in BCBA recruiting, retention, and supervision infrastructure
• Geographic concentration in 2–4 metros with strong demand
• Multi-payer contracting beyond your dominant commercial or Medicaid relationship
• Outcome measurement infrastructure
• Compliance program maturity

Common Mistakes ABA Owners Make in Sales

1. Pricing expectations anchored to 2020–2021 multiples — the market has reset; pricing expectations should be 2026-anchored
2. Engaging a single inbound buyer — competitive process discipline matters more than ever in this segment
3. Underestimating clinical model scrutiny — buyers diligence this hard; weak preparation produces deep discounts
4. Inadequate BCBA retention narrative — agencies that can’t tell a credible story about BCBA durability lose value
5. Generic non-healthcare advisory — ABA M&A requires healthcare expertise

---

Strategic Implications

The 2026 ABA M&A market is selectively active. Quality operators with strong BCBA infrastructure, clean clinical models, defensible compliance, and competitive payer mix continue to attract premium multiples. The market reset from the 2020–2021 peak has reduced multiples but increased the durability of outcomes for sellers who fit the new buyer criteria.

If you operate an ABA or autism services agency and would like to understand current market conditions for your specific business, contact us for a confidential conversation.